Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica
The New England Journal of Medicine
•
June 03, 2026
Secukinumab improves relapsed polymyalgia remission
Secukinumab plus prednisone taper improved sustained remission in relapsed polymyalgia rheumatica. *Phase 3 randomized controlled trial; Level 2 (OCEBM).
- Level of evidence
- Level 2 (OCEBM)
- DocG quality score
- 7.7 / 10
Read the full summary free
Patients, intervention, outcomes, results, and clinical applicability in about 300 words — plus new summaries in your inbox 3× per week.
Sign in with Google
